Literature DB >> 28826525

Small Molecule PET Tracers for Transporter Imaging.

Michael R Kilbourn1.   

Abstract

As the field of PET has expanded and an ever-increasing number and variety of compounds have been radiolabeled as potential in vivo tracers of biochemistry, transporters have become important primary targets or facilitators of radiotracer uptake and distribution. A transporter can be the primary target through the development of a specific high-affinity radioligand: examples are the multiple high-affinity radioligands for the neuronal membrane neurotransmitter or vesicular transporters, used to image nerve terminals in the brain. The goal of a radiotracer might be to study the function of a transporter through the use of a radiolabeled substrate, such as the application of 3-O-[11C]methyl]glucose to measure rates of glucose transport through the blood-brain barrier. In many cases, transporters are required for radiotracer distributions, but the targeted biochemistries might be unrelated: an example is the use of 2-deoxy-2-[18F]FDG for imaging glucose metabolism, where initial passage of the radiotracer through cell membranes requires the action of specific glucose transporters. Finally, there are transporters such as p-glycoprotein that function to extrude small molecules from tissues, and can effectively work against successful uptake of radiotracers. The diversity of structures and functions of transporters, their importance in human health and disease, and their role in therapeutic drug disposition suggest that in vivo imaging of transporter location and function will continue to be a point of emphasis in PET radiopharmaceutical development. In this review, the variety of transporters and their importance for in vivo PET radiotracer development and application are discussed. Transporters have thus joined the other major protein targets such as G-protein coupled receptors, ligand-gated ion channels, enzymes, and aggregated proteins as of high interest for understanding human health and disease.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28826525     DOI: 10.1053/j.semnuclmed.2017.05.005

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  6 in total

1.  Drug Transporters in Xenobiotic Disposition and Pharmacokinetic Prediction.

Authors:  Qingcheng Mao; Yurong Lai; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2018-05       Impact factor: 3.922

Review 2.  DARK Classics in Chemical Neuroscience: Cocaine.

Authors:  Lindsey R Drake; Peter J H Scott
Journal:  ACS Chem Neurosci       Date:  2018-04-24       Impact factor: 4.418

3.  Blood-brain barrier link to human cognitive impairment and Alzheimer's Disease.

Authors:  Giuseppe Barisano; Axel Montagne; Kassandra Kisler; Julie A Schneider; Joanna M Wardlaw; Berislav V Zlokovic
Journal:  Nat Cardiovasc Res       Date:  2022-02-07

4.  Development of Positron Emission Tomography Radiotracers for the GABA Transporter 1.

Authors:  Alexandra R Sowa; Allen F Brooks; Xia Shao; Bradford D Henderson; Philip Sherman; Janna Arteaga; Jenelle Stauff; Adam C Lee; Robert A Koeppe; Peter J H Scott; Michael R Kilbourn
Journal:  ACS Chem Neurosci       Date:  2018-05-24       Impact factor: 4.418

Review 5.  The role of brain vasculature in neurodegenerative disorders.

Authors:  Melanie D Sweeney; Kassandra Kisler; Axel Montagne; Arthur W Toga; Berislav V Zlokovic
Journal:  Nat Neurosci       Date:  2018-09-24       Impact factor: 24.884

6.  Vascular dysfunction-The disregarded partner of Alzheimer's disease.

Authors:  Melanie D Sweeney; Axel Montagne; Abhay P Sagare; Daniel A Nation; Lon S Schneider; Helena C Chui; Michael G Harrington; Judy Pa; Meng Law; Danny J J Wang; Russell E Jacobs; Fergus N Doubal; Joel Ramirez; Sandra E Black; Maiken Nedergaard; Helene Benveniste; Martin Dichgans; Costantino Iadecola; Seth Love; Philip M Bath; Hugh S Markus; Rustam Al-Shahi Salman; Stuart M Allan; Terence J Quinn; Rajesh N Kalaria; David J Werring; Roxana O Carare; Rhian M Touyz; Steve C R Williams; Michael A Moskowitz; Zvonimir S Katusic; Sarah E Lutz; Orly Lazarov; Richard D Minshall; Jalees Rehman; Thomas P Davis; Cheryl L Wellington; Hector M González; Chun Yuan; Samuel N Lockhart; Timothy M Hughes; Christopher L H Chen; Perminder Sachdev; John T O'Brien; Ingmar Skoog; Leonardo Pantoni; Deborah R Gustafson; Geert Jan Biessels; Anders Wallin; Eric E Smith; Vincent Mok; Adrian Wong; Peter Passmore; Frederick Barkof; Majon Muller; Monique M B Breteler; Gustavo C Román; Edith Hamel; Sudha Seshadri; Rebecca F Gottesman; Mark A van Buchem; Zoe Arvanitakis; Julie A Schneider; Lester R Drewes; Vladimir Hachinski; Caleb E Finch; Arthur W Toga; Joanna M Wardlaw; Berislav V Zlokovic
Journal:  Alzheimers Dement       Date:  2019-01       Impact factor: 16.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.